aTyr Pharma’s Resolaris obtains EMA orphan drug designation to treat FSHD

Biotherapeutics firm aTyr Pharma has received orphan drug designation from the European Commission (EC) for its Resolaris to treat facioscapulohumeral muscular dystrophy (FSHD).
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news